Citadel Advisors
QNRX

Citadel Advisors’s Quoin Pharmaceuticals QNRX Stock Holding History

Citadel Advisors’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Buy
+32,519
New +$295K ﹤0.01% 11278
2024
Q2 		– Sell
-308
Closed -$10.2K – 15188
2024
Q1 		$10.2K Buy
+308
New +$30.4K ﹤0.01% 13467
2023
Q1 		– Sell
-25
Closed -$15.1K – 15358
2022
Q4 		$15.1K Sell
25
-17
-40% -$12.8K ﹤0.01% 13346
2022
Q3 		$39K Buy
42
+38
+950% +$78.2K ﹤0.01% 11772
2022
Q2 		$9K Buy
+4
New +$15.9K ﹤0.01% 12605
2021
Q3 		– Sell
-1
Closed -$60K – 14483
2021
Q2 		$60K Hold
1
– – ﹤0.01% 13249
2021
Q1 		$52K Buy
+1
New +$69.8K ﹤0.01% 12886
2019
Q4 		– Hold
0
– -$12K – 9626
2019
Q3 		– Hold
0
– – – 9024
2019
Q2 		– Hold
0
– – – 8983
2019
Q1 		– Hold
0
– -$62K – 9754
2018
Q4 		– Hold
0
– – – 8431

Other funds holding QNRX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Citadel Advisors's QNRX Position: Q1 2026 in Review

Citadel Advisors opened a new position in Quoin Pharmaceuticals (QNRX) in Q1 2026: 32,519 shares worth $215K. The stake represents ﹤0.01% of the portfolio and ranks #11278 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in QNRX as recently as Q1 2024.

Citadel Advisors first reported a position in QNRX in Q1 2021 and has held it in 7 quarters since. 22 funds tracked by Wall St. Rank hold QNRX as of Q1 2026.

  • Citadel Advisors held 32,519 shares of Quoin Pharmaceuticals worth $215K as of Q1 2026.
  • Quoin Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
  • Quoin Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11278 holding.
  • Citadel Advisors first reported a position in Quoin Pharmaceuticals in Q1 2021 and has held it in 7 quarters since.
  • 22 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.